Login to Your Account



Potential $217M Alliance

Pfizer Deal Puts Karo Bio in Pole Position for ROR-Gamma Race

By Catherine Shaffer
BioWorld International Contributing Writer

Wednesday, January 4, 2012
Pfizer Inc. has signed a collaboration agreement with Karo Bio AB, of Stockholm, Sweden, for the development of small-molecule modulators of retinoic acid-related orphan receptor (ROR-gamma), an enticing newer target with relevance for autoimmune disease.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription